Impax Labs To Market Pristiq To Neurologists, Implementing Earlier Deal With Wyeth
This article was originally published in The Pink Sheet Daily
Co-promotion deal will assist Impax in ramping up its commercial team ahead of the launch of its own branded specialty drugs.
You may also be interested in...
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.